In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 15, No. 705 ( 2023-07-19)
Abstract:
Chimeric antigen receptor (CAR) T cell therapy is highly effective against several hematologic malignancies, including multiple myeloma (MM); however, they often have adverse effects on healthy tissues that also express the targeted antigen. To overcome this, Vander Mause et al. have developed an affinity-tuning approach using CD229 as a target antigen against MM. Authors generated low-affinity CD229 CAR T cells and overexpressed c-Jun to retain effective tumor targeting and elimination while removing its off-tumor toxicity in vitro and in vivo. This represents a promising approach that can be used to improve the wide array of CAR T cell therapies currently in use. —Dorothy Hallberg
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.add7900
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2023
Permalink